News

May 22, 2020May 22, 2020

Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Rubraca (rucaparib) for treating patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations who have previously received ... Read more

May 21, 2020May 22, 2020

FDA Approves Lynparza for mCRPC Patients with Mutations in DNA Repair Genes

News

The U.S. Food and Drug Administration has approved the oral therapy Lynparza (olaparib) for treating men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including ... Read more

May 15, 2020May 15, 2020

Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows

News

Adding Erleada (apalutamide) to androgen deprivation therapy (ADT) significantly extends the lives of men with non-metastatic castration-resistant prostate cancer (CRPC) by more than one year, a final analysis of the SPARTAN ... Read more

May 8, 2020May 8, 2020

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

News

Men with metastatic castration-resistant prostate cancer (mCRPC) showing evidence of active immune responses in their tumors live longer without disease progression after being treated with Yervoy (ipilimumab), a Phase 2 ... Read more

April 27, 2020April 27, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

News, syndicated

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their ... Read more

April 24, 2020April 24, 2020

FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer

News

Myovant Sciences has filed an application with the U.S. Food and Drug Administration (FDA) seeking approval of relugolix to treat men with advanced prostate cancer. The new drug application (NDA) proposes a single ... Read more

April 17, 2020April 17, 2020

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

News

A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data from ... Read more

April 10, 2020April 24, 2020

Gene Variant Seen to Promote Castration-resistant Disease in Whites

News

A variant in a gene that promotes the production of testosterone by prostate cancer cells is linked to poorer survival and the development of castration-resistant disease in Caucasians with metastatic ... Read more

April 3, 2020April 3, 2020

Winners Named for Prostate Cancer Foundation’s TRUE Love Awareness Contest

News

The 3rd annual TRUE Love Contest of the Prostate Cancer Foundation (PCF), which features inspirational stories from patients and caregivers to raise disease awareness, has selected two winners. Chosen by ... Read more

March 27, 2020March 27, 2020

Guidelines for Radiation Therapy with COVID-19 Urge Less Treatment

News

New guidelines for radiation oncologists suggest that, during the COVID-19 pandemic, interactions with healthcare professionals should be done remotely where possible, and treatments should be avoided or delayed to minimize strains ... Read more